Novartis Buys Ebewe’s Injectable Cancer Drug Business
This article was originally published in The Pink Sheet Daily
Executive Summary
The €925 million deal provides Novartis’ Sandoz division with a fast-growing generic oncology business and expanded development portfolio.
You may also be interested in...
Is Teva Among Finalists In Bidding For Germany's Ratiopharm? (Part 2 of 2)
Ratiopharm would bring market share, geographic diversification, and an attractive OTC business - if the price is right.
Is Teva Among Finalists In Bidding For Germany's Ratiopharm? (Part 2 of 2)
Ratiopharm would bring market share, geographic diversification, and an attractive OTC business - if the price is right.
Generic Injectables: Pharma Takes A Shot At A Growing Market
When it comes to drugs driving generic growth, usually blockbusters such as Lipitor and Plavix come to mind. But there is another area of the generic market that offers plenty of dynamic potential - sterile drugs administered by injection or infusion